- Report
- January 2025
- 150 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- May 2024
- 160 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- April 2024
- 642 Pages
Global
From €3436EUR$3,600USD£2,879GBP
- Report
- May 2024
- 166 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- May 2024
- 87 Pages
Global
From €2815EUR$2,950USD£2,359GBP
- Report
- March 2024
- 76 Pages
Global
From €2815EUR$2,950USD£2,359GBP
- Report
- March 2024
- 123 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- November 2024
- 100 Pages
United States
From €5679EUR$5,950USD£4,758GBP
- Report
- April 2024
- 199 Pages
North America
From €1432EUR$1,500USD£1,199GBP
- Report
- April 2024
- 235 Pages
Middle East, Africa
From €1432EUR$1,500USD£1,199GBP
- Report
- April 2024
- 233 Pages
Europe
From €1432EUR$1,500USD£1,199GBP
- Report
- April 2024
- 237 Pages
Asia Pacific
From €1432EUR$1,500USD£1,199GBP
- Report
- May 2024
- 78 Pages
North America
From €2815EUR$2,950USD£2,359GBP
- Report
- May 2024
- 70 Pages
Africa, Middle East
From €2815EUR$2,950USD£2,359GBP
- Report
- May 2024
- 86 Pages
Asia Pacific
From €3293EUR$3,450USD£2,759GBP
- Report
- May 2024
- 90 Pages
Europe
From €3293EUR$3,450USD£2,759GBP
- Report
- March 2024
- 60 Pages
Africa, Middle East
From €2815EUR$2,950USD£2,359GBP
- Report
- March 2024
- 64 Pages
Asia Pacific
From €3293EUR$3,450USD£2,759GBP
- Report
- March 2024
- 65 Pages
Europe
From €3293EUR$3,450USD£2,759GBP
- Report
- March 2024
- 59 Pages
North America
From €2815EUR$2,950USD£2,359GBP

Schizophrenia is a mental disorder characterized by abnormal social behavior and a distorted perception of reality. It is one of the most disabling and emotionally devastating mental illnesses, affecting approximately 1% of the population worldwide. Symptoms of schizophrenia can include hallucinations, delusions, disorganized speech and behavior, and cognitive deficits.
The schizophrenia market within the context of mental health is a rapidly growing sector, driven by the increasing prevalence of the disorder and the need for better treatments. The market is expected to benefit from the development of novel drugs and therapies, as well as the increasing awareness of mental health issues. Additionally, the increasing focus on personalized medicine and the development of digital health technologies are expected to drive the market growth.
Some of the key players in the schizophrenia market include Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Otsuka Pharmaceutical, Sunovion Pharmaceuticals, Allergan, and Merck. Show Less Read more